Literature DB >> 3998494

Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro.

K D Cooper, K Kang, S C Chan, J M Hanifin.   

Abstract

Peripheral blood mononuclear leukocytes (MNL) from patients with atopic dermatitis spontaneously produce large amounts of IgE in vitro. These cells also show markedly elevated levels of cAMP phosphodiesterase (PDE) which may be responsible for the observed abnormal cAMP responsiveness. Treatment of atopic dermatitis MNL with varying concentrations of the cAMP PDE inhibitor Ro 20-1724 resulted in progressively decreasing amounts of IgE synthesis, statistically significant at the 10(-4) M and 10(-5) M concentrations. There was a close correlation between PDE inhibition and inhibition of IgE synthesis, r = 0.93, p less than 0.05. To define the cellular target of the drug, we used monoclonal antibodies directed toward MNL subsets (Lyt 3, OKT8, OKT4, monocyte-myeloid) in a modified "panning" method to perform experiments with purified subsets. With untreated subsets, removal of OKT4-positive cells significantly reduced IgE synthesis; readdition of OKT4-positive cells enhanced IgE synthesis. OKT8 cells and monocytes did not affect IgE synthesis. Pretreatment of T cell-depleted MNL with Ro 20-1724 resulted in significantly more inhibition of IgE synthesis than did pretreatment of T enriched cells prior to recombination with the reciprocal untreated subset and subsequent culture. Similarly, pretreatment of monocyte-depleted cells resulted in significantly more inhibition of IgE synthesis than pretreatment of monocyte-enriched cells prior to recombination and culture. The majority of the effect appeared to be mediated by a direct effect on the B cells. However, some inhibition of IgE synthesis was also achieved through pretreatment of T enriched cells. Since pretreatment of isolated suppressor/cytotoxic or helper/inducer T-cell subsets did not give the same degree of inhibition as with unfractionated T cells, a T-T interaction may be involved in this aspect. The imidazolidinone derivative, Ro 20-1724, significantly and consistently inhibited both the elevated cAMP phosphodiesterase activity and the elevated spontaneous IgE synthesis of MNL from patients with atopic dermatitis. These findings demonstrate a previously undescribed link between cAMP PDE levels and in vitro IgE synthesis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3998494     DOI: 10.1111/1523-1747.ep12272486

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  10 in total

Review 1.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Authors:  T J Torphy; B J Undem
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

Review 2.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

3.  The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways.

Authors:  D T Schmidt; N Watson; G Dent; E Rühlmann; D Branscheid; H Magnussen; K F Rabe
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

4.  Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis.

Authors:  K H Banner; N M Roberts; C P Page
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 5.  Pharmacophysiology of atopic dermatitis.

Authors:  J M Hanifin
Journal:  Clin Rev Allergy       Date:  1986-02

Review 6.  Recent advances in treatment strategies for atopic dermatitis.

Authors:  Thomas Christian Roos; Stefan Geuer; Sabine Roos; Harald Brost
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Cyclic nucleotide phosphodiesterases in the human lung.

Authors:  G Dent; H Magnussen; K F Rabe
Journal:  Lung       Date:  1994       Impact factor: 2.584

Review 8.  Revisiting Therapies for Atopic Dermatitis that Failed Clinical Trials.

Authors:  Gaurav Agnihotri; Peter A Lio
Journal:  Clin Drug Investig       Date:  2020-05       Impact factor: 2.859

9.  Modulation of oxazolone-induced hypersensitivity in mice by selective PDE inhibitors.

Authors:  I Moodley; Y Sotsios; B Bertin
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

10.  New and developing therapies for atopic dermatitis.

Authors:  Tamar Hajar; João Renato Vianna Gontijo; Jon M Hanifin
Journal:  An Bras Dermatol       Date:  2018 Jan-Feb       Impact factor: 1.896

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.